EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today reported financial and operating results for the third quarter ended September 30, 2012.
Quarter and Recent Highlights
Completed all clinical studies for the VIBEX™ MTX Medi-Jet™ product ahead of schedule including a recently completed clinical pharmacokinetic study, an actual human use study and a human factors usability study. The NDA remains on track for a Q1 2013 filing.
